Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Frontier Medicines Corporation has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This single prosecution matter is being handled within 1 distinct art unit. The narrow scope of current activity suggests a highly specific focus for the company's immediate patenting efforts in this sector. With only a single pending office action, the company's current interaction with the patent office is extremely limited.
The portfolio involves a distinct examiner, RAHMANI, NILOOFAR, who is responsible for the busiest examiner pending action. This examiner accounts for the total pending workload for the company. With only the same art unit and examiner involved, the current prosecution profile is centralized, reflecting the single pending office action reported in the data. The presence of a distinct art unit and a distinct examiner for the pending office action suggests that the company's current biotechnology filings are being handled by a very specific examination group.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.5% | -2.9% |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707499 | KRAS G12C INHIBITORS | RAHMANI, NILOOFAR | 1691 | §112 | Non-Final OA | — | Pending | May 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial